David Onion

Summary

Affiliation: University of Birmingham
Country: UK

Publications

  1. ncbi The CD4+ T-cell response to adenovirus is focused against conserved residues within the hexon protein
    David Onion
    CRUK Institute for Cancer Studies, University of Birmingham, Birmingham B15 2TT, UK
    J Gen Virol 88:2417-25. 2007
  2. ncbi A lentiviral vector that activates latent human immunodeficiency virus-1 proviruses by the overexpression of tat and that kills the infected cells
    David Macías
    Departamento de Biologia Experimental, Universidad de Jaen, Jaen, Spain
    Hum Gene Ther 20:1259-68. 2009
  3. ncbi Antivector and tumor immune responses following adenovirus-directed enzyme prodrug therapy for the treatment of prostate cancer
    David Onion
    Cancer Research UK Institute of Cancer Sciences, University of Birmingham, Birmingham, UK
    Hum Gene Ther 20:1249-58. 2009
  4. ncbi Viral gene therapy strategies: from basic science to clinical application
    Lawrence S Young
    Cancer Research UK Institute for Cancer Studies, University of Birmingham Medical School, UK
    J Pathol 208:299-318. 2006
  5. ncbi Adenovirus vector-specific T cells demonstrate a unique memory phenotype with high proliferative potential and coexpression of CCR5 and integrin alpha4beta7
    Geothy Chakupurakal
    University of Birmingham, Birmingham, UK
    AIDS 24:205-10. 2010
  6. ncbi Adenovirus type 5 interactions with human blood cells may compromise systemic delivery
    Mark Lyons
    Department of Clinical Pharmacology, University of Oxford, Radcliffe Infirmary, Woodstock Road, Oxford OX2 6HE, UK
    Mol Ther 14:118-28. 2006

Collaborators

  • Steven P Lee
  • Lawrence S Young
  • Geothy Chakupurakal
  • David Macías
  • Vivien Mautner
  • Mark Lyons
  • Mark Cobbold
  • Paul A H Moss
  • Francisco Martin
  • Ricardo Oya
  • Francisco Luque
  • Luisa Saniger
  • Nicky K Green
  • Sue Phipps
  • Kerry D Fisher
  • Sarah Hale
  • Leonard W Seymour
  • Ratna Rajaratnam
  • Kriss Aslan
  • Miriam Bazan-Peregrino

Detail Information

Publications6

  1. ncbi The CD4+ T-cell response to adenovirus is focused against conserved residues within the hexon protein
    David Onion
    CRUK Institute for Cancer Studies, University of Birmingham, Birmingham B15 2TT, UK
    J Gen Virol 88:2417-25. 2007
    ..Three CD4 T-cell epitopes are described, which map to highly conserved regions of the hexon protein...
  2. ncbi A lentiviral vector that activates latent human immunodeficiency virus-1 proviruses by the overexpression of tat and that kills the infected cells
    David Macías
    Departamento de Biologia Experimental, Universidad de Jaen, Jaen, Spain
    Hum Gene Ther 20:1259-68. 2009
    ..In summary, we have developed a vector system that is efficient in activating latent HIV-1 proviruses but that needs further improvement to kill infected cells...
  3. ncbi Antivector and tumor immune responses following adenovirus-directed enzyme prodrug therapy for the treatment of prostate cancer
    David Onion
    Cancer Research UK Institute of Cancer Sciences, University of Birmingham, Birmingham, UK
    Hum Gene Ther 20:1249-58. 2009
    ....
  4. ncbi Viral gene therapy strategies: from basic science to clinical application
    Lawrence S Young
    Cancer Research UK Institute for Cancer Studies, University of Birmingham Medical School, UK
    J Pathol 208:299-318. 2006
    ....
  5. ncbi Adenovirus vector-specific T cells demonstrate a unique memory phenotype with high proliferative potential and coexpression of CCR5 and integrin alpha4beta7
    Geothy Chakupurakal
    University of Birmingham, Birmingham, UK
    AIDS 24:205-10. 2010
    ..This led to the suggestion that the Ad based vector may boost the number of CD4 chemokine receptor 5 (CCR5) T cells, target cells for HIV infection...
  6. ncbi Adenovirus type 5 interactions with human blood cells may compromise systemic delivery
    Mark Lyons
    Department of Clinical Pharmacology, University of Oxford, Radcliffe Infirmary, Woodstock Road, Oxford OX2 6HE, UK
    Mol Ther 14:118-28. 2006
    ..This may increase antigen presentation following intravenous injection, while blood cell binding may both decrease access of the virus to extravascular targets and inhibit infection of cells to which the virus does gain access...